Local production of the unidentified mRNA vaccine could begin in the fourth quarter or early in 2022, foreign ministry spokeswoman Le Thi Thu Hang told a regular news briefing, adding that Vietnam ...

Alongside research and production of vaccines to prevent African swine fever, Vietnam is increasingly mastering the necessary ...

HANOI (Reuters) - French pharmaceutical company Sanofi said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local partner Vietnam Vaccine Company ...

Vietnam's vaccine market, valued at $945M, is expanding due to increased government funding for the EPI, rising private sector involvement, and demand for life-course immunization. Key regions ...

From this important success, new scientific elements with far-sighted vision have been implanted in the field of vaccine production. By 1980, Sabin vaccine was introduced into the expanded ...

Vietnam has also mastered many vaccine technologies such as those for inactivated vaccines, antitoxin vaccines, and subunit vaccines. However, according to Phuong, the current limitation in Vietnam's ...

Ultimately, Vietnam's success in vaccine production serves as both a lesson and an inspiration. The Philippines has the ...

Announcing the results of the Sputnik V clinical trial in medical journal The Lancet, the manufacturer has said the vaccine has a 91.6 percent efficacy after the first shot, and 91.8 percent for those ...

HANOI (Reuters) - Vietnam's health ministry called for the acceleration of its COVID-19 vaccine rollout on Friday as the expiry date of the Southeast Asian ...

HANOI, May 27 (Reuters) - French pharmaceutical company Sanofi (SASY.PA), opens new tab said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local ...

Vietnam's vaccine market, valued at $945M, is expanding due to increased government funding for the EPI, rising private sector involvement, and deman Tuesday, 02 January 2024 12:17 GMT عربي ...

Vietnam's vaccine market, valued at $945M, is expanding due to increased government funding for the EPI, rising private sector involvement, and demand for life-course immunization. Key regions include ...